AZD1208 is a potent, ATP-competitive, pan-PIM kinase inhibitor designed to target PIM1, 2 and 3.11 It has been investigated in preclinical models of AML and prostate cancer.12,13 In AML cell lines, inhibition of cell growth by AZD1208 correlated with PIM1 expression. The gene discussed is PIM1; the disease is prostate cancer.